AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.245

0.000

Volume:1.56M

Turnover:382.76K

Market Cap:147.10M

PE:-4.93

High:0.255

Open:0.245

Low:0.240

Close:0.245

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:2.21

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.050

ROE:-594.54%

ROA:-29.36%

PB:-9.97

PE(LYR):-4.93

Loading ...

Overview Company News Filings

Concept

Novel Coronavirus Treatment-0.88%

Pharmaceutical Companies-1.24%

Capital Flow

Inflow:

Outflow:

News

Australia's Dimerix Rises on Patent Approval in Mexico

Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate

MT Newswires Live

Dimerix Ltd-Dimerix Dmx-652 Granted Mexican Composition of Matter Patent

THOMSON REUTERS

Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketf.com/stock/DXB.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.245,"timestamp":1789711920000,"preClose":0.245,"halted":0,"volume":1558801,"delay":0,"changeRate":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-18 16:12:00 AEST","open":0.245,"high":0.255,"low":0.24,"amount":382758,"amplitude":0.061224,"askPrice":0.255,"askSize":56188,"bidPrice":0.245,"bidSize":49638,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789948800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.245,"openAndCloseTimeList":[[1789689600000,1789711200000]],"volumeRatio":2.2084727207843358,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.245,"auctionPrice":0.245,"auctionVolume":31691,"auction":3,"marketStatus":"盘后竞价","timestamp":1789711801809}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":2.2084727207843358,"shares":600396776,"dividePrice":0,"high":0.255,"amplitude":0.061224,"preClose":0.245,"low":0.24,"week52Low":0.157,"pbRate":"-9.97","psRate":"23.15","week52High":0.665,"institutionHeld":0,"latestPrice":0.245,"committee":-0.061894,"eps":-0.0497,"divideRate":0,"volume":1558801,"delay":0,"ttmEps":-0.0497,"open":0.245,"prevYearClose":0.55,"prevWeekClose":0.25,"prevMonthClose":0.28,"prevQuarterClose":0.205,"fiveDayClose":0.25,"twentyDayClose":0.31,"sixtyDayClose":0.19,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667632159","title":"Australia's Dimerix Rises on Patent Approval in Mexico","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632159?lang=en_us&edition=fundamental","pubTime":"2026-09-14 11:59","pubTimestamp":1789358350,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix rises on patent approval in Mexico** Shares of Australia's DimerixDXB.AXrise as much as 10% to A$0.275, marking their biggest pct gain since August 20** Clinical-stage biopharmaceutical company says Mexico has granted a patent for DMX-652, a drug candidate for acute kidney injury** The patent expands protection for DMX-652 in Mexico, one of Latin America's largest pharmaceutical markets** Co says the approval strengthens the commercial potential of DMX-652, following a similar approval for the drug in U.S.** YTD down 53.6%, including the session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4N45604Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667368026","title":"Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2667368026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667368026?lang=en_us&edition=fundamental","pubTime":"2026-09-14 08:06","pubTimestamp":1789344401,"startTime":"0","endTime":"0","summary":"Dimerix  said the Mexican Institute of Industrial Property  granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.The patent grant \"N-cyanopyrrolidines with activity as USP30 inhibitors\" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","DXB.AU","DMX","BK7067","USRD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667633298","title":"Dimerix Ltd-Dimerix Dmx-652 Granted Mexican Composition of Matter Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2667633298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667633298?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:39","pubTimestamp":1789339172,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260913:nTUE3BDS1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","DXB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800459","title":"Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800459","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800459?lang=en_us&edition=fundamental","pubTime":"2026-09-04 08:40","pubTimestamp":1788482421,"startTime":"0","endTime":"0","summary":"Dimerix  secured non-dilutive loan facility agreements with a syndicate of Australian and US-based lenders to access up to AU$34 million, according to a Friday Australian bourse filing.This included a previously announced initial facility agreement of AU$10 million with Skiptan, per the filing. The firm confirmed that it was funded through to completion of the Action3 phase 3 trial in DMX-200, as well as the planned phase 2 clinical trial in DMX-652.The facility carries an interest rate of 10% per year, compounding annually, the company said. The receipt of the initial 50% draw-down is anticipated by Sept. 18, and the remainder is expected to take place at the firm's discretion on or before March 31, 2027.The facility provides the flexibility for Dimerix to elect to take further commitments for up to a total of AU$50 million on or before March 31, 2027.The biopharmaceutical company's shares were up 4% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","BK7508","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DXB.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Novel Coronavirus Treatment","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":-0.008804},{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.012418}]}}